A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

Cancer

Volumn 122, Issue 21, 2016, Pages 3327-3335

  Chari, Ajai ^a   Htut, Myo ^b   Zonder, Jeffrey A ^c   Fay, Joseph W ^d   Jakubowiak, Andrzej J ^e   Levy, Joan B ^f   Lau, Kenneth ^a   Burt, Steven M ^c   Tunquist, Brian J ^g   Hilder, Brandi W ^g   Rush, Selena A ^g   Walker, Duncan H ^g   Ptaszynski, Mieke ^g   Kaufman, Jonathan L ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f Multiple Myeloma Research Consortium   (United States)

^g ARRAY BIOPHARMA INC   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

bortezomib; dexamethasone; filanesib; multiple myeloma; neoplasm recurrence; proteasome inhibitors; recurrent refractory

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; FILANESIB; FILGRASTIM; LENALIDOMIDE; POMALIDOMIDE; ANTINEOPLASTIC AGENT; THIADIAZOLE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLURRED VISION; BRONCHITIS; CANCER RECURRENCE; CHOLECYSTITIS; COUGHING; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HYPERURICEMIA; HYPONATREMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; THIADIAZOLES;

EID: 84991640167     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30174     Document Type: Article

References (14)

1. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867–874.
2. Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26:149–157.
3. Tunquist BJ, Woessner RD, Walker DH. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther. 2010;9:2046–2056.
4. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100:194–199.
5. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426:671–676.
6. Woessner R, Tunquist B, Walker D, Rana S, Orlowski R, Kuhn D. Combination of the KSP inhibitor ARRY-520 with bortezomib causes sustained tumor regressions and significantly increased time to regrowth in bortezomib sensitive and resistant models of multiple myeloma. Presented in abstract form at: American Association for Cancer Research (AACR) 102nd Annual Meeting; April 2–6, 2011; Orlando, FL. Abstract 2550.
7. Heidari N, Hicks MA, Harada H. GX15–070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis. 2010;1:e76.
8. Richardson PG, Sonneveld P, Schuster MW, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.
9. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–440.
10. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed October 13, 2014.
11. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
12. Shah JJ, Zonder JA, Cohen AD, et al. A phase 1/2 trial of the KSP inhibitor ARRY-520 in relapsed/refractory multiple myeloma [abstract]. Blood. 2010;116(21). Abstract 1959.
13. Tunquist B, Brown K, Hingorani G, et al. Alpha 1-acid glycoprotein (AAG) is a potential patient selection biomarker for improved clinical activity of ARRY-520 in relapsed and refractory multiple myeloma (MM). Presented in abstract form at: 18th Congress of the EHA; June 13–16, 2013; Stockholm, Sweden. Abstract P786.
14. Murphy MP, Caraher E. Mcl-1 is vital for neutrophil survival. Immunol Res. 2015;62:225–233.